uniQre N.V. presented an update on the Phase I/II trial of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, continuing to share long-term patient data and evaluation of biomarker effectiveness.
uniQre N.V. presented an update on the Phase I/II trial of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, continuing to share long-term patient data and evaluation of biomarker effectiveness.